Correction to “Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing”
Year: 2026
Type: erratum
Abstract: Hu, Z., Escalera-Joy, A., Ashcraft, E., Acharya, R., Jeha, S., Cheng, C. and Pui, C.-H. (2024), Clinical Risk Factors for High-Dose Methotrexate-Induced Oral Mucositis Following Individualized Dosing. Cancer Med, 13: e70351. https://doi.org/10.1002/cam4.70351. In paragraph 1, section 2.2 | MTX Concentration Monitoring, the text “using the ARK diagnostics homogeneous enzyme immunoassay (ARK Diagnostics', Fremont, CA)” was incorrect. It should be changed to “using assay by a fluorescence polarization immunoassay technique with a TDx/FLx analyzer (Abbott Diagnostics, Chicago, Illinois, U.S.A.).” The referenced citation 20 should read “P. R. Oeltgen, W. A. Shank Jr, R. A. Blouin, T. Clark.,” “Clinical Evaluation of the Abbott TDx Fluorescence Polarization Immunoassay Analyzer,” “Therapeutic Drug Monitoring 6 no. 3 (1984): 360–367.” We apologize for these errors.
Source: Cancer Medicine
DOI: 10.1002/cam4.71478
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,700
OpenAlex ID: W7128495166
Cites:
Cited by:
Related to: